Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GELESIS HOLDINGS, INC.GLS · Entity 109516 | Director | May 06, 2022 | May 09, 2022 |
| Inogen IncINGN · Entity 2083 | EVP, Finance, & CFO | December 01, 2021 | December 03, 2021 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | Director | February 15, 2023 | February 17, 2023 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Operating Officer | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GELESIS HOLDINGS, INC.
Report date May 06, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,095 |
Reported balance
After 2022-05-06 transaction · row 1
1 source rowRow 1 · 2022-05-06 · Grant · Acquired 51,095 · Balance 51,095 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time.
Inogen Inc
Report date December 01, 2021 · Filed December 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,902 |
Last balance in matching sequence
After 2021-12-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-12-01 · Exercise / conversion · Acquired 546 · Balance 34,392 F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. Row 2 · 2021-12-01 · Tax withholding · Disposed 490 · Balance 33,902 F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021. F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,915 |
Reported balance
After 2021-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-01 · Exercise / conversion · Disposed 546 · Balance 4,915 F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error.
F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021.
F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 71,428 |
Reported balance
After 2023-02-15 transaction · row 1
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 71,428 · Balance 71,428 |
Sight Sciences, Inc.
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 639,449 |
Reported balance
After 2026-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,260 · Balance 639,449 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 20:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 25,260 | $8.85 | $223,626.78 |
DisclosureSEC source: 0001193125-26-414281 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 639,449 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:32 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 24,184 | $5.36 | $129,626.24 |
DisclosureSEC source: 0001193125-26-296590 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 664,709 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.19 to $5.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 192,669 shares of Common Stock, and (ii) 472,040 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:42 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 12,728 | $5.12 | $65,167.36 |
DisclosureSEC source: 0001193125-26-230957 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 688,893 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $4.91 to $5.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 169,810 shares of Common Stock, and (ii) 519,083 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:28 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 25,874 | $3.48 | $90,041.52 |
DisclosureSEC source: 0001193125-26-142235 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 701,621 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.43 to $3.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 156,788 shares of Common Stock, and (ii) 544,833 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:48 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 127,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039557 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,495 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $825,000 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. F2 · balance_after: Includes (i) 135,620 shares of Common Stock, and (ii) 591,875 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 00:03 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 9,647 | $7.48 | $72,159.56 |
DisclosureSEC source: 0001193125-26-004979 · ownership.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,983 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F3 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:03 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 10,896 | $7.82 | $85,206.72 |
DisclosureSEC source: 0001193125-26-004979 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609,630 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:35 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 23,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-280303 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,526 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing December 31, 2025 and continuing through September 30, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $150,000 of shares of Common Stock as determined by the stock price on the grant date, November 11, 2025. The RSUs have no expiration date. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 19,948 | $3.30 | $65,828.40 |
DisclosureSEC source: 0001193125-25-230560 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,520 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 19,260 | $4.10 | $78,927.48 |
DisclosureSEC source: 0000950170-25-094427 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,468 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| May 19, 2025 Filed May 22, 2025 00:38 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 13,066 | $3.48 | $45,430.48 |
DisclosureSEC source: 0000950170-25-075987 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 636,728 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 01:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 19,397 | $2.31 | $44,787.67 |
DisclosureSEC source: 0000950170-25-050861 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,794 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 01:56 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 286,738 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039083 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,191 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2025 and continuing through December 31, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $800,000 divided by the closing price of the Common Stock on the grant date, which was March 11, 2025. The RSUs have no expiration date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 02:47 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 10,102 | $3.52 | $35,579.24 |
DisclosureSEC source: 0000950170-25-002531 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,453 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.465 to $3.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 01:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 10,130 | $6.08 | $61,590.40 |
DisclosureSEC source: 0000950170-24-112704 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,555 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 23:50 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 10,497 | $6.21 | $65,207.36 |
DisclosureSEC source: 0000950170-24-081724 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,685 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| May 17, 2024 Filed May 21, 2024 00:56 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 13,066 | $5.42 | $70,869.98 |
DisclosureSEC source: 0000950170-24-062639 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,182 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2024 Filed Apr 4, 2024 23:19 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 10,123 | $5.08 | $51,414.72 |
DisclosureSEC source: 0000950170-24-041976 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,248 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:36 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 315,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016701 · ownership.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,371 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2024 and continuing through December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,350,000 divided by the closing price of the Common Stock on the grant date, which was February 14, 2024. The RSUs have no expiration date. F2 · balance_after: Includes 17,950 shares of Common Stock issuable upon the Reporting Person's exercise of options that shall vest within 60 days of the date hereof subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:55 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 71,800 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0000899243-23-012788 · doc4.xml · derivative · entry 2 Bauerlein Alison · CIK 0001596080 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,800 Underlying: Common Stock · 71,800 shares Expires 2033-05-09 F2 · shares: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable as to 25% of the underlying shares on April 3, 2024, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on April 3, 2027. F2 · derivative.exercise_date: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable as to 25% of the underlying shares on April 3, 2024, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on April 3, 2027. Read SEC document |
| May 09, 2023 Filed May 12, 2023 01:55 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 103,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-012788 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing May 15, 2024 and continuing through May 15, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. The RSUs have no expiration date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:09 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantClass A Common Stock | 71,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004029 · form4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,428 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:12 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014976 · form4.xml · derivative · entry 1 Bauerlein Alison · CIK 0001596080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 100% of the shares upon the Reporting Person's cessation of Service Relationship (as defined in the Issuer's 2021 Stock Option and Incentive Plan) that qualifies as a "separation from service" within the meaning of Section 409A of the Internal Revenue Code (the "Separation Date"), provided that the Separation Date occurs on or after June 14, 2023 (and for the avoidance of doubt, if the Separation Date occurs prior to June 14, 2023, the restricted stock units shall expire unvested). F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 100% of the shares upon the Reporting Person's cessation of Service Relationship (as defined in the Issuer's 2021 Stock Option and Incentive Plan) that qualifies as a "separation from service" within the meaning of Section 409A of the Internal Revenue Code (the "Separation Date"), provided that the Separation Date occurs on or after June 14, 2023 (and for the avoidance of doubt, if the Separation Date occurs prior to June 14, 2023, the restricted stock units shall expire unvested). Read SEC document |
| May 06, 2022 Filed May 9, 2022 16:15 UTC | GELESIS HOLDINGS, INC. GLS · Entity 109516 | GrantCommon Stock | 51,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-057518 · tm2214815-1_4seq1.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,095 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2 · shares: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time. F1 · price: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:47 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 115 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001062993-21-012666 · form4.xml · derivative · entry 1 Bauerlein Alison · CIK 0001596080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115 Underlying: Class A Common Stock · 115 shares Expires 2031-12-08 F1 · derivative.exercise_date: The option becomes exercisable for 33% of the shares on December 3, 2022, 33% of the shares on December 3, 2023 and 34% of the shares on December 3, 2024. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 22:27 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 70,560 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001062993-21-012404 · form4.xml · derivative · entry 1 Bauerlein Alison · CIK 0001596080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,560 Underlying: Class A Common Stock · 70,560 shares Expires 2031-12-03 F1 · derivative.exercise_date: The option becomes exercisable for 33% shares on December 3, 2022, 33% of the shares on December 3, 2023 and 34% of the shares on December 3, 2024. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067951 · doc4.xml · derivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,915 Underlying: Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. F4 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 490 | $29.66 | $14,533.40 |
DisclosureSEC source: 0001209191-21-067951 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,902 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021. F1 · balance_after: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067951 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:39 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054885 · doc4.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F5 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. F5 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:39 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054885 · doc4.xml · derivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. F4 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:39 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 616 | $60.57 | $37,311.12 |
DisclosureSEC source: 0001209191-21-054885 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,691 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on September 1, 2021. F1 · balance_after: Shares beneficially owned are 271 shares less than the previously filed Form 4s due to an error reporting the shares withheld to cover the Reporting Person's tax withholding liability on June 1, 2021. An amendment to the original Form 4 has been filed to correct the error. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:39 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054885 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares beneficially owned are 271 shares less than the previously filed Form 4s due to an error reporting the shares withheld to cover the Reporting Person's tax withholding liability on June 1, 2021. An amendment to the original Form 4 has been filed to correct the error. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:39 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054885 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares beneficially owned are 271 shares less than the previously filed Form 4s due to an error reporting the shares withheld to cover the Reporting Person's tax withholding liability on June 1, 2021. An amendment to the original Form 4 has been filed to correct the error. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,397 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · derivative · entry 6 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,895 Underlying: Common Stock · 1,397 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,397 | $80.33 | $112,215.70 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F3 · price: Represents the weighted average share price of an aggregate total of 1,397 shares sold in the price range of $80.12 to $80.68 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 1,397 | $38.54 | $53,840.38 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,235 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,292 Underlying: Common Stock · 8,235 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 8,235 | $80.01 | $658,922.70 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F2 · price: Represents the weighted average share price of an aggregate total of 8,235 shares sold in the price range of $80.00 to $80.16 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 23:56 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 8,235 | $38.54 | $317,376.90 |
DisclosureSEC source: 0001209191-21-049484 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 20:15 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,632 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-21-048495 · doc4.xml · derivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,527 Underlying: Common Stock · 9,632 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 20:15 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 9,632 | $75.02 | $722,564.71 |
DisclosureSEC source: 0001209191-21-048495 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F2 · price: Represents the weighted average share price of an aggregate total of 9,632 shares sold in the price range of $75.00 to $75.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 20:15 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 9,632 | $38.54 | $371,217.28 |
DisclosureSEC source: 0001209191-21-048495 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037852 · doc4.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 Underlying: Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. F4 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037852 · doc4.xml · derivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253 Underlying: Common Stock · 252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F3 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. F3 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:57 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 343 | $60.34 | $20,696.62 |
DisclosureSEC source: 0001209191-21-037852 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 F1 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037852 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037852 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Sep 3, 2021 22:38 UTC Amendment | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054884 · doc4a.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 Underlying: Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F6 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. F6 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. Read SEC document |
| June 01, 2021 Filed Sep 3, 2021 22:38 UTC Amendment | Inogen Inc INGN · Entity 2083 | Exercise / conversionRestricted Stock Unit · Derivative | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054884 · doc4a.xml · derivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253 Underlying: Common Stock · 252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F5 · derivative.exercise_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. F5 · derivative.expiration_date: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.